Gilead Sciences has completed its previously announced acquisition of Germany-based biotechnology company Tubulis GmbH, strengthening its oncology pipeline with next-generation antibody-drug conjugate (ADC) technologies designed to improve precision cancer treatment and expand therapeutic options for difficult-to-treat tumors.
The acquisition marks a significant move by Gilead to deepen its presence in the rapidly evolving ADC market, an area of oncology focused on targeted therapies that deliver cancer-fighting agents directly to tumor cells while limiting damage to healthy tissue.
Tubulis, a private clinical-stage biotechnology company headquartered in Munich, Germany, specializes in developing next-generation ADCs aimed at enhancing the selective delivery of therapeutic payloads to tumors. Gilead said the deal brings both advanced pipeline assets and a proprietary technology platform intended to maximize patient benefit through more targeted drug delivery and improved anti-tumor activity.
The company noted that Tubulis’ technologies are designed to produce ADCs with superior biophysical properties, allowing for stronger and more sustained delivery of treatment payloads directly to tumors. Such characteristics could potentially translate into longer-lasting anti-cancer effects and improved outcomes for patients with hard-to-treat cancers.
A key component of the acquisition is Tubulis’ lead clinical candidate, TUB-040, a sodium-dependent phosphate transport protein 2B (NaPi2b)-directed topoisomerase-I inhibitor ADC. The therapy has demonstrated promising activity in patients with platinum-resistant ovarian cancer, an aggressive form of disease where treatment options remain limited and recurrence rates are high.
Gilead also gains TUB-030, a 5T4-directed ADC currently being investigated across a range of solid tumor indications. The asset complements the company’s broader oncology ambitions and expands its ADC pipeline into multiple cancer settings.
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, said the acquisition builds on an existing relationship between the two companies and reflects confidence in Tubulis’ scientific capabilities.
According to O’Day, Gilead’s two-year collaboration with Tubulis reinforced confidence in the biotechnology company’s team, research programs and technology platform. He added that combining the strengths of both organizations could help accelerate the development of new therapies for some of the most challenging forms of cancer.
Financially, Gilead acquired all outstanding equity of Tubulis for $3.15 billion in upfront consideration on a cash-free, debt-free basis. The agreement also includes up to $1.85 billion in additional contingent milestone payments tied to future development and commercial achievements.
Despite becoming part of Gilead, Tubulis’ operations will remain in Munich, where the company’s workforce will continue its activities under a newly established Tubulis ADC Innovation Center. Gilead said the center will serve as a hub for integrated discovery, manufacturing and clinical development efforts aimed at advancing the next generation of ADC therapies.
The acquisition further underscores growing pharmaceutical industry investment in precision oncology and ADC platforms as companies race to develop more targeted cancer treatments with improved efficacy and safety profiles.